Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hesperetin and sucrose on blood glucose and energy intake
NCT05705596Phase 1Completed
- Sponsor
- University of Vienna
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hesperetin in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Vienna. Primary endpoints: Blood glucose concentration, Appetite score and 1 more. Started Jan 2023; status: completed.
02
Drugs
hesperetin
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05705596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705596.